Rasayana licensed SYN-020, a gastrointestinal candidate, from Theriva Biologics in a deal potentially worth up to $36 million.
Longevity News
In a deal with Theriva Biologics potentially worth as much as $36 million, Rasayana has gained a gastrointestinal ass...
Source: FierceBiotech - All • Published: 18 Feb 2026, 15:47
Continue exploring
Related longevity signals
Lifespan.ioA Million-Person Study Finds a Protective Metabolic GeneHuman genetics research exploring metabolic regulation and disease risk, previewing an article that examines gene-based discoveries and potential therapeutic pathways.PR NewswireAureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryA biotech funding story about a startup scaling AI-native drug discovery and building biological foundation models; a look at its R&D strategy and platform.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Nature - BiotechnologySEQURNA enhances FLASH-seq gene detection while eliminating DTT dependenceSEQURNA-focused methods article presenting a comparative benchmark of a synthetic thermostable RNase inhibitor for improved single-cell, full-length RNA-seq workflows.